Application of Artificial Intelligence in Precision Medicine and Healthcare
NCT06879210 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2025-06-04
Summary
This study aims to propose an intelligent health robot that utilizes remote intelligent robots to assist patients with disease-related issues, enabling them to address their problems promptly.
Conditions
Interventions
- DEVICE
-
Mobile device.(phone)
Develop a mobile device \[Disease Assistance Consultation\] to help patients promptly understand their disease and how to care for it. After a 4-week trial period, conduct interviews with participants to determine whether using the mobile device can increase participants' knowledge and improve the quality of healthcare.
Sponsors & Collaborators
-
Yi Ting Yeh
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- DEVICE_FEASIBILITY
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-04-19
- Primary Completion
- 2026-04-19
- Completion
- 2026-07-19
Countries
- Taiwan
Study Locations
More Related Trials
-
Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis
NCT07146425 ·Status: RECRUITING
-
A Study in Patients With Myasthenia Gravis in China
NCT06700616 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
NCT05332587 ·Status: UNKNOWN ·Phase: PHASE3
-
Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
NCT04590716 ·Status: COMPLETED
-
A Prospective Cohort Study of Myasthenia Gravis in China
NCT06006832 ·Status: RECRUITING
-
Detecting Fatigue From Voice in Generalised Myasthenia Gravis
NCT07033559 ·Status: NOT_YET_RECRUITING
-
Psychological Health and Adverse Childhood Experiences in Myasthenia Gravis: Online Mental Health BMI Learning Program
NCT07291713 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
NCT06688435 ·Status: RECRUITING ·Phase: PHASE1
-
The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy
NCT01727193 ·Status: COMPLETED ·Phase: PHASE3
-
TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
NCT04182984 ·Status: RECRUITING
-
Predictors and Prognostic Factors of Myasthenia Gravis Outcome
NCT05214612 ·Status: RECRUITING
-
Markers of Favorable Response to Complement Inhibitors Therapy
NCT06455709 ·Status: RECRUITING
-
Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis
NCT00004682 ·Status: TERMINATED ·Phase: NA
-
Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis
NCT05716035 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis
NCT07071246 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
NCT06704269 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)
NCT06965309 ·Status: TERMINATED ·Phase: NA
-
Cognitive Functioning in People With Myasthenia Graivs: Impact on Daily Life Activities, Work, Disability and Quality of Life
NCT06718855 ·Status: COMPLETED
-
Seronegative Myasthenia Gravis - Efgartigimod IV
NCT06587867 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
NCT05067348 ·Status: RECRUITING ·Phase: PHASE2
-
Acupuncture in Myasthenia Gravis (AcuMG)
NCT05230082 ·Status: COMPLETED ·Phase: NA
-
Exploring Outcomes and Characteristics of Myasthenia Gravis 2
NCT06002945 ·Status: ACTIVE_NOT_RECRUITING
-
Interleukin and Autoantibodies in Myasthenia Gravis.
NCT05301153 ·Status: UNKNOWN
-
Biomarkers in Autoimmune Disease of Nervous System
NCT06502015 ·Status: RECRUITING
-
Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
NCT05332210 ·Status: COMPLETED ·Phase: PHASE3